Projects per year
Personal profile
Education
- 2010 Ph.D., Graduate Institute of Medicine, Kaohsiung Medical University, Taiwan
- 2005 MS, Department of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Taiwan
- 2004 Bachelor, Department of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Taiwan
Experience
- 2022- Professor, Graduate Institute of Pharmacognosy, Taipei Medical University, Taiwan
- 2017-2022 Associate Professor, Graduate Institute of Pharmacognosy, Taipei Medical University, Taiwan
- 2016-2017 Assistant Professor, Ph.D. Program in Biotechnology Research and Development, Taipei Medical University
- 2015-2017 Assistant Professor, Ph.D. Program for Translational Medicine, Taipei Medical University
- 2012-2017 Assistant Professor, Graduate Institute of Pharmacognosy, Taipei Medical University, Taiwan
- 2010-2011 Adjunct Assistant Professor, Department and Graduate of Aquaculture, National Kaohsiung Marine University, Taiwan
Awards
- 2021 科技部吳大猷先生紀念獎_藥學領域
-
2020 國家新創獎_新創精進
- 2019 國家新創獎_學研新創
- 2012 戰國策創業競賽 (特優獎)
- 2008 National Innovation Award (The First Prize)
Fingerprint
- 1 Similar Profiles
Network
-
Development of Antagonistic Bace-2 Antibodies to Improve Type 2 Diabetes by Inducing Pancreatic Beta-Cells Proliferation( II )
8/1/22 → 7/31/23
Project: A - Government Institution › b - Ministry of Science and Technology
-
Development of Anti-Α9nachr/Anti-Cd3 Bispecific Antibody to One-Step Construct an Armed T Cell Immunotherapy for Efficiently Eliminating Breast Tumor( III )
8/1/22 → 7/31/23
Project: A - Government Institution › b - Ministry of Science and Technology
-
開發串聯式人類第二型乙型轉化生長因子受體重組蛋白以去除細胞外液中乙型轉化生長因子之醫療應用
7/1/22 → 2/28/23
Project: A - Government Institution › b - Ministry of Science and Technology
-
以第二型糖尿病模式小鼠模式小鼠評估新穎抗體藥物對於血糖控制與胰島保護療效
7/1/22 → 2/28/23
Project: A - Government Institution › b - Ministry of Science and Technology
-
利用內生性報告基因轉殖鼠以開發第一型糖尿病之治療藥物及其應用策略
1/1/22 → 12/31/22
Project: A - Government Institution › a - National Health Research Institutes
-
Comparing the Therapeutic Mechanism and Immune Response of Human and Mouse Mesenchymal Stem Cells in Immunocompetent Mice With Acute Liver Failure
Wang, C. H., Chen, C. Y., Wang, K. H., Kao, A. P., Chen, Y. J., Lin, P. H., Chen, M., Wu, T. Y., Cheng, J. J., Lee, K. D. & Chuang, K. H., Jan 30 2023, In: Stem cells translational medicine. 12, 1, p. 39-53 15 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Citation (Scopus) -
Rational design of synthetically tractable HDAC6/HSP90 dual inhibitors to destroy immune-suppressive tumor microenvironment
Wu, T. Y., Chen, M., Chen, I. C., Chen, Y. J., Chen, C. Y., Wang, C. H., Cheng, J. J., Nepali, K., Chuang, K. H. & Liou, J. P., Apr 2023, In: Journal of Advanced Research. 46, p. 159-171Research output: Contribution to journal › Article › peer-review
Open Access2 Citations (Scopus) -
A novel anti-tumor/anti-tumor-associated fibroblast/anti-mPEG tri-specific antibody to maximize the efficacy of mPEGylated nanomedicines against fibroblast-rich solid tumor
Chen, M., Sheu, M. T., Cheng, T. L., Roffler, S. R., Lin, S. Y., Chen, Y. J., Cheng, Y. A., Cheng, J. J., Chang, H. Y., Wu, T. Y., Kao, A. P., Ho, Y. S. & Chuang, K. H., Jan 7 2022, In: Biomaterials Science. 10, 1, p. 202-215 14 p.Research output: Contribution to journal › Article › peer-review
Open Access3 Citations (Scopus) -
A universal in silico V(D)J recombination strategy for developing humanized monoclonal antibodies
Hsieh, Y. C., Liao, J. M., Chuang, K. H., Ho, K. W., Hong, S. T., Liu, H. J., Huang, B. C., Chen, I. J., Liu, Y. L., Wang, J. Y., Tsai, H. L., Su, Y. C., Wang, Y. T. & Cheng, T. L., Jan 31 2022, In: Journal of Nanobiotechnology. 20, 1, p. 58 58.Research output: Contribution to journal › Article › peer-review
Open Access -
Bispecific T-cell engagers non-covalently decorated drug-loaded PEGylated nanocarriers for cancer immunochemotherapy
Cheng, W. J., Chuang, K. H., Lo, Y. J., Chen, M., Chen, Y. J., Roffler, S. R., Ho, H. O., Lin, S. Y. & Sheu, M. T., Apr 2022, In: Journal of Controlled Release. 344, p. 235-248 14 p.Research output: Contribution to journal › Article › peer-review
4 Citations (Scopus)
Datasets
-
Additional file 1 of A universal in silico V(D)J recombination strategy for developing humanized monoclonal antibodies
Wang, Y. (Creator), Huang, B. (Creator), Hsieh, Y. (Creator), Ho, K. (Creator), Cheng, T. (Creator), Wang, J. (Creator), Liu, H. (Creator), Tsai, H. (Creator), Liao, J. (Creator), Liu, Y. (Creator), Hong, S. (Creator), Chen, I. (Creator), Su, Y. (Creator) & Chuang, K. (Creator), Figshare, 2022
DOI: 10.6084/m9.figshare.19101789.v1, https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_of_A_universal_in_silico_V_D_J_recombination_strategy_for_developing_humanized_monoclonal_antibodies/19101789/1
Dataset
-
Humanized bispecific antibody (mPEG × HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer
Cheng, Y. (Creator), Wu, T. (Contributor), Wang, Y. (Contributor), Cheng, T. (Creator), Chen, I. (Creator), Lu, Y. (Contributor), Chuang, K. (Contributor), Wang, C. (Contributor), Chen, C. (Creator), Lin, R. (Creator), Chen, H. (Creator), Liao, T. (Contributor), Liu, E. (Contributor) & Chen, F. (Creator), Figshare, 2020
DOI: 10.6084/m9.figshare.c.5105096.v1, https://springernature.figshare.com/collections/Humanized_bispecific_antibody_mPEG_HER2_rapidly_confers_PEGylated_nanoparticles_tumor_specificity_for_multimodality_imaging_in_breast_cancer/5105096/1
Dataset
-
Bispecific antibodies (anti-mPEG/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors
Chen, L. (Contributor), Lin, S. (Contributor), Sheu, M. (Contributor), Ho, Y. (Contributor), Su, C. (Contributor), Chen, M. (Contributor), Ho, H. (Contributor) & Chuang, K. (Contributor), Unknown Publisher, 2018
DOI: 10.6084/m9.figshare.6213620, https://doi.org/10.6084%2Fm9.figshare.6213620
Dataset
-
Additional file 1 of Humanized bispecific antibody (mPEG × HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer
Liu, E. (Contributor), Wang, C. (Contributor), Chuang, K. (Contributor), Chen, F. (Creator), Wu, T. (Contributor), Chen, C. (Creator), Chen, I. (Creator), Lin, R. (Creator), Wang, Y. (Contributor), Lu, Y. (Contributor), Liao, T. (Contributor), Chen, H. (Creator), Cheng, T. (Creator) & Cheng, Y. (Creator), Figshare, 2020
DOI: 10.6084/m9.figshare.12885938.v1, https://doi.org/10.6084%2Fm9.figshare.12885938.v1
Dataset
-
Bispecific antibodies (anti-mPEG/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors
Su, C. (Contributor), Chen, M. (Contributor), Chen, L. (Contributor), Ho, Y. (Contributor), Ho, H. (Contributor), Lin, S. (Contributor), Chuang, K. (Contributor) & Sheu, M. (Contributor), Unknown Publisher, May 2 2018
DOI: 10.6084/m9.figshare.6213620.v1, https://tandf.figshare.com/articles/Bispecific_antibodies_anti-mPEG_anti-HER2_for_active_tumor_targeting_of_docetaxel_DTX_-loaded_mPEGylated_nanocarriers_to_enhance_the_chemotherapeutic_efficacy_of_HER2-overexpressing_tumors/6213620/1
Dataset